Chapter I. Diabetic Peripheral Neuropathy

Treating Diabetic Neuropathy: Present Strategies and Emerging Solutions

Saad Javed¹, Uazman Alam^1,2, Rayaz A. Malik^1,3

Manuscript submitted April 25, 2015; accepted April 30, 2015.

Keywords: diabetic peripheral neuropathy, small fiber, polyneuropathy, alpha-lipoic acid, nerve fiber density

Abstract

Diabetic peripheral neuropathies (DPN) are a heterogeneous group of disorders caused by neuronal dysfunction in patients with diabetes. They have differing clinical courses, distributions, fiber involvement (large or small), and pathophysiology. These complications are associated with increased morbidity, distress, and healthcare costs. Approximately 50% of patients with diabetes develop peripheral neuropathy, and the projected rise in the global burden of diabetes is spurring an increase in neuropathy. Distal symmetrical polyneuropathy (DSPN) with painful diabetic neuropathy, occurring in around 20% of diabetes patients, and diabetic autonomic neuropathy (DAN) are the most common manifestations of DPN. Optimal glucose control represents the only broadly accepted therapeutic option though evidence of its benefit in type 2 diabetes is unclear. A number of symptomatic treatments are recommended in clinical guidelines for the management of painful DPN, including antidepressants such as amitriptyline and duloxetine, the γ-aminobutyric acid analogues gabapentin and pregabalin, opioids, and topical agents such as capsaicin. However, monotherapy is frequently not effective in achieving complete resolution of pain in DPN. There is a growing need for head-to-head studies of different single-drug and combination pharmacotherapies. Due to the ubiquity of autonomic innervation in the body, DAN causes a plethora of symptoms and signs affecting cardiovascular, urogenital, gastrointestinal, pupillomotor, thermoregulatory, and sudomotor systems. The current treatment of DAN is largely symptomatic, and does not correct the underlying autonomic nerve deficit. A number of novel potential candidates, including erythropoietin analogues, angiotensin II receptor type 2 antagonists, and sodium channel blockers are currently being evaluated in phase II clinical trials.

Fulltext: HTML , PDF (352KB)

This article has been cited by other articles:

	Early vs. late intervention of high fat/low dose streptozotocin treated C57Bl/6J mice with enalapril, α-lipoic acid, menhaden oil or their combination: Effect on diabetic neuropathy related endpoints Yorek MS, Obrosov A, Shevalye H, Coppey LJ, Kardon RH, Yorek MA Neuropharmacology 2017. 116:122-131
	Photobiostimulation reverses allodynia and peripheral nerve damage in streptozotocin-induced type 1 diabetes Rocha IR, Ciena AP, Rosa AS, Martins DO, Chacur M Lasers Med Sci 2017. 32(3):495-501
	Efficacy of Administration of an Angiotensin Converting Enzyme Inhibitor for Two Years on Autonomic and Peripheral Neuropathy in Patients with Diabetes Mellitus Didangelos T, Tziomalos K, Margaritidis C, Kontoninas Z, Stergiou I, Tsotoulidis S, Karlafti E, Mourouglakis A, Hatzitolios AI J Diabetes Res 2017. 2017:6719239
	Diabetic neuropathy: summary of treatment options Chirayath HH Vascul Dis Ther 2017. 2(2):1-2
	PainVision: a simple, rapid, and objective method with potential for screening diabetic peripheral neuropathy Gu Y, Zhao Y, Dai M, Ma J, Feng B, Li X, Wang Q Int J Clin Exp Med 2017. 10(1):1043-1050
	Wherefore Art Thou, O Treatment for Diabetic Neuropathy? Malik RA Int Rev Neurobiol 2016. 127:287-317